EUCTR2010-020141-26-DE进行中（未招募）不适用
A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase IIa Study to Investigate the Effects of 100mg AZD2423 as an oral tablet in Subjects with Mild COPD Following Segmental Endobronchial LPS Instillation. - Investigation of the effect of oral treatment with 100mg AZD2423 in subjects with mild COPD.
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For inclusion in the study subjects should fulfil the following criteria:
- •1- Male or female of non-child bearing potential. Only women of non-child bearing potential are included in the study i.e. women who are permanently or surgically sterilised or post menopausal.
- •2- = 40 years of age at Visit 1
- •3- Clinical diagnosis of COPD (GOLD stage 1)
- •4- FEV1 = 80% of the predicted normal post-bronchodilator at Visit 1 (GOLD stage 1)
- •5- FEV1/FVC <70% post-bronchodilator at Visit 1 (GOLD stage 1)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 4
排除标准
- •Subjects should not enter the study if any of the following exclusion criteria are fulfilled:
- •1- Any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk or influence the way the drug works
- •2- Any clinically relevant abnormal findings in physical examination, blood or urine test results, vital signs or ECG at Visit 1 that may put the subject at risk during the study, affect their ability or take part or influence the results of the study
- •3- A past history or current indication of renal (kidney) failure
- •4- Subjects at risk of active tuberculosis or of disease reactivation
- •5- Subjects who have had any clinically significant illness within 4 weeks before Visit 2 (start of treatment)
研究者
相似试验
已完成
2 期
A Single-Centre, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ARA 290 Administered Intravenously to End-Stage Renal Disease Patientsend-stage renal disease10038430NL-OMON33202Araim Pharmaceuticals, Inc12
撤回
2 期
Rapamycin impact on muscle strength and endurance in older adultssarcopeniaMusculoskeletal - Other muscular and skeletal disordersACTRN12622000480785Dr Brad Stanfield Ltd40
招募中
2 期
Rapamycin impact on muscle strength and endurance in older adultsSarcopeniaMusculoskeletal - Other muscular and skeletal disordersACTRN12624000790549Dr Brad Stanfield Ltd40
撤回
1 期
A Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral AD-6626 in Normal, Healthy VolunteersThis study is for healthy volunteers. The intended use of the investigational product is the treatment of Fanconi AnemiaBlood - Haematological diseasesHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersACTRN12615000601538Aldea Pharmaceuticals24
招募中
1 期
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Tolerability of KDF-07002 in Healthy, Adult VolunteersThis trial is to assess safety and tolerability of KDF-07002 in healthy adult males and dose not focus on any particular health condition or problemOther - Research that is not of generic health relevance and not applicable to specific health categories listed aboveACTRN12609000086268ucleus Network, Ltd.54